Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A neuroblastoma arising from the retina.
Biomarker and diagnostic research for retinal neuroblastoma has been reported in the published literature.
4 clinical trials registered, 2 recruiting. Interventions under study include other interventions, biologic therapy, and drug therapy. Pipeline includes 2 PHASE1. Research is primarily sponsored by academic and government institutions.
143 publications have been identified in PubMed for retinal neuroblastoma. Research spans Review / Meta-Analysis (38%), Basic Science / Preclinical (23%), and Epidemiology / Natural History (14%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 55 |
Data assembled from 3 of 12 sources · Last updated Nov 3, 2026, 11:13 AM UTC
Laboratory research | 33 | 23% |
Disease patterns and progression | 20 | 14% |
New treatment approaches | 14 | 10% |
Clinical study results | 9 | 6% |
Patient case studies | 6 | 4% |
Testing and diagnosis research | 4 | 3% |
Other research | 2 | 1% |
Asghar E (2026). [PMID: 41401403](https://pubmed.ncbi.nlm.nih.gov/41401403/). *Ocul Immunol Inflamm*. [Review / Meta-Analysis]
Sidhu AS (2026). [PMID: 40539965](https://pubmed.ncbi.nlm.nih.gov/40539965/). *Ophthalmic Plast Reconstr Surg*. [Review / Meta-Analysis]
Liv T (2026). [PMID: 41395640](https://pubmed.ncbi.nlm.nih.gov/41395640/). *Histopathology*. [Review / Meta-Analysis]
Gudenas BL (2026). [PMID: 41791379](https://pubmed.ncbi.nlm.nih.gov/41791379/). *Cancer Cell*. [Basic Science / Preclinical]
Vaithianathan AM (2026). [PMID: 42187581](https://pubmed.ncbi.nlm.nih.gov/42187581/). *Curr Oncol*. [Review / Meta-Analysis]
Sujjitjoon J (2026). [PMID: 41521230](https://pubmed.ncbi.nlm.nih.gov/41521230/). *Sci Rep*. [Gene Therapy / Novel Therapeutics]
Zhang MG (2026). [PMID: 41191430](https://pubmed.ncbi.nlm.nih.gov/41191430/). *Mol Cancer Res*. [Basic Science / Preclinical]
Kaur K (2026). [PMID: 31424860](https://pubmed.ncbi.nlm.nih.gov/31424860/). *Unknown Journal*. [Epidemiology / Natural History]
Bowman R (2026). [PMID: 41408393](https://pubmed.ncbi.nlm.nih.gov/41408393/). *Eye (Lond)*. [Epidemiology / Natural History]
Feiner ER (2026). [PMID: 42211790](https://pubmed.ncbi.nlm.nih.gov/42211790/). *Ocul Oncol Pathol*. [Review / Meta-Analysis]
AI-curated news mentioning retinal neuroblastoma
Updated Sep 28, 2026
A case report details metastatic neuroblastoma originating from an ovarian immature teratoma in a 16-year-old female. This unique presentation highlights the complexities of diagnosing and treating rare pediatric cancers.
A new engineered allosteric biosensor has been developed for the in situ detection of DNA glycosylases, which could enhance risk stratification and monitor drug resistance in neuroblastoma. This advancement may improve treatment strategies for patients with this challenging cancer.
A new in vivo cascade cyclic amplification strategy has been developed to detect MYCN mRNA expression levels in neuroblastoma. This innovative approach could enhance the understanding of MYCN's role in the disease.